1. Scrip
  2. >>Business
  3. >>Deals

Vertex Builds Type 1 Diabetes Reach And Flexibility With ViaCyte

 
• By Jessica Merrill

Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.

multiple pawns
Vertex wants to expand its Type 2 diabetes options • Source: Shutterstock

Vertex Pharmaceuticals Incorporated will acquire the privately held stem cell therapy developer ViaCyte, Inc. for $320m in cash to expand its pipeline and development flexibility in type 1 diabetes, the company announced on 11 July. ViaCyte's portfolio will complement Vertex's internal effort to develop its allogeneic stem cell-derived, insulin-producing islet cell therapy, VX-880, and bring a functional cure for type 1 diabetes to market, according to Vertex.

"This acquisition brings us tools, technologies and assets that have the potential to accelerate our goal of bringing a curative...

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.